Promoted Content
Promoted Content

Find Novel Neurology Drugs in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Topiramate

            Therapeutic Area: Neurology Product Name: ET-101

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2020

            Details:

            Marketing Application for ET-101 was submitted for monotherapy to treat primary general tonic-clonic seizures in patients at least two years old, adjunctive therapy for treatment of partial-onset seizures, and as preventative treatment of migraine in patients, two years old.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CRISPR based gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $415.0 million Upfront Cash: $15.0 million

            Deal Type: Collaboration October 06, 2020

            Details:

            Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 17, 2020

            Details:

            Following initial efforts focused on multiple sclerosis (MS), PicnicHealth, Roche and Genentech recently expanded their collaboration to support Huntington’s disease (HD), paroxysmal nocturnal hemoglobinuria (PNH), and hemophilia.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Opioid based transdermal medications

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Nutriband

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 16, 2020

            Details:

            With this acquisition Pocono plans to consolidate capabilities at both facilities to expand on enhancing revenue stream opportunities and in-house product development, specifically our abuse deterrent technology for opioid based transdermal medications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sarepta Therapeutics

            Deal Size: Undisclosed Upfront Cash: $72.5 million

            Deal Type: Collaboration June 23, 2020

            Details:

            Alliance to explore the utility of engineered exosomes developed with Codiak’s engEx™ Platform to deliver gene therapy, gene editing and RNA technologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dexmedetomidine Hydrochloride

            Therapeutic Area: Neurology Product Name: Precedex

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 22, 2020

            Details:

            Vizient has signed an agreement with Pfizer to add six drugs identified as “essential medications” to its Novaplus® Enhanced Supply Program, part of Vizient’s private label pharmacy solution.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ENX-101

            Therapeutic Area: Neurology Product Name: ENX-101

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Nan Fung Life Sciences

            Deal Size: $32.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 18, 2020

            Details:

            The Company plans to use the proceeds from the financing to support the clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

            Therapeutic Area: Neurology Product Name: Trappsol Cyclo

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 17, 2020

            Details:

            The final report to FDA states that the drug showed a favorable safety profile as well as encouraging observations of benefit. Safety was monitored by MRIs, ECGs, laboratory safety assessments, and adverse events, all of which supported a favorable safety profile.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABX-002

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: ARCH Venture Partners

            Deal Size: $76.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing June 09, 2020

            Details:

            Proceeds will be used to advance Autobahn’s lead program candidate, ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS) and adrenomyeloneuropathy (AMN).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 22, 2020

            Details:

            Presentation will focus on the development of novel therapeutics focused on treating Central Nervous System (CNS) indications via the gut-brain axis at the American Society of Clinical Psychopharmacology (ASCP).

            PharmaCompass